Every year, more than 75,000 people with sickle cell disease are admitted to hospitals. GMI-1070

is currently being studied as a potential treatment for vaso-occlusive crisis (VOC), the primary trigger for hospitalizations related to sickle cell disease.

At GlycoMimetics, we actively conduct promising research

and seek to establish unique collaborations in our pursuit of new treatments for people with serious diseases.

Patients with blood cancers have an urgent need for new medical treatment options. Preclinical studies

of novel therapies for hematologic cancers are underway.

Who We Are and What We Do

At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell disease and various cancers.  Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments.

GlycoMimetics is a privately held clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, especially those with high unmet needs. Since the company’s inception in 2003, we have developed a robust, diversified product pipeline.

The value of GlycoMimetics’ scientific approach and the potential of our product pipeline have been validated by investments from prestigious investors like New Enterprise Associates (NEA) and the venture funds of Novartis and Genzyme, as well as by our major partnership with Pfizer.